United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs

United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.65, $0.40 better than the analyst estimate of $1.25. Revenue for the quarter came in at $243.82 million versus the consensus estimate of $233.41 million.

United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance
• Bath & Body Works, Inc. (BBWI) Tops Q2 EPS by 38c, Offers FY27 EPS Guidance